Please login to the form below
classical Hodgkin's lymphoma
This page shows the latest classical Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC
Tyvyt’s major rival is Merck &Co’s Keytruda (pembrolizumab), which holds approvals across a range of NSCLC indications. ... Tyvyt has also been approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma (cHL).
Latest news
-
Boehringer Ingelheim to manufacture first biologic in China under new reforms
BeiGene's PD-1 inhibitor tislelizumab was approved in China last week for use in classical Hodgkin’s lymphoma patients who have already received at least two prior lines of treatment. ... The country’s national medicines regulator – the Chinese
-
BeiGene bags FDA approval for first product Brukinsa in lymphoma
MCL is an aggressive type of non-Hodgkin’s lymphoma (NHL) for which Brukinsa also claimed a breakthrough designation from the FDA earlier this year. ... BeiGene is also developing PD-1 inhibitor tislelizumab – which has been filed for approval in
-
BeiGene gets speedy US review for lymphoma drug zanubrutinib
The US regulator awarded the status for zanubrutinib as a second-line treatment for mantle cell lymphoma (MCL), an aggressive type of non-Hodgkin’s lymphoma for which the drug also ... In addition to zanubrutinib, BeiGene is also developing PD-1
-
Chi-Med goes for third IPO in Hong Kong
1 inhibitor tislelizumab for relapsed/refractory classical Hodgkin’s lymphoma. ... The current pace of development of the biotech ecosystem in China is remarkable,” said Simon To, Chi-Med’s chairman.
-
Innovent gears up for PD-1 inhibitor launch in China
Tyvyt (sintilimab) was jointly developed by Innovent and partner Eli Lilly in China and was approved by the National Medical Products Administration (NMPA) for relapsed or refractory classical Hodgkin's lymphoma ... The home-grown PD-1 inhibitors join
More from news
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
One of the best known pharma leaders in China, Dr Wu’s most recent achievement was to build Pfizer into one of the top multinational firms in China. ... CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- How to create content for health professionals
- Sanofi to cut US insulin prices by up to 78% in January 2024
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- 2023 PM Society Awards – winners announced
- Next congress, please: making the most of virtual pharmaceutical congresses
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- AstraZeneca announces major expansion of Canadian research footprint
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Regeneron’s application for Eylea in retinopathy of prematurity accepted for FDA priority review
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
